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At Risk for Huntington's Disease
HD is a genetically caused brain disorder that causes uncontrollable bodily movements and robs
people's ability to walk, talk, eat, and think. The final result is a slow, ugly death. Children of parents
with HD have a 50-50 chance of inheriting the disease. There is no cure or treatment.
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To develop treatments for a disease, researchers and physicians first need
to understand how its symptoms evolve and how they affect people’s lives.
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In early August, I traveled to the University of Iowa in Iowa City to donate
blood, urine, and saliva samples, undergo a motor coordination exam and
brain MRI scan, and perform a battery of cognitive and mood tests for the
long-term research study Neurobiological Predictors of Huntington’s
Disease, best known as PREDICT-HD, one of the largest public-private
research projects in the history of the quest to defeat the disease.
My biological samples will become part of a bio-repository at the National
Institute of Neurological Disorders and Stroke (NINDS), a division of the
National Institutes of Health (NIH) located just outside Washington, D.C.
Researchers from around the world can apply for access to these materials.
In studying gene-positive, asymptomatic people like me, the scores of
researchers working at the University of Iowa, 26 other PREDICT centers
in the U.S. and abroad, and many other institutions can try to analyze how
the early symptoms of HD develop.
They are also seeking to identify HD “biomarkers” in the blood, cerebral
spinal fluid (CSF), and brains of the study participants, who include
formerly at-risk individuals who tested negative for HD. These individuals
serve as a control, or comparison, group to ascertain which changes in the
gene-positive people are specifically caused by HD.
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Gene Veritas in preparation for PREDICT-HD MRI scan (photo by Sarah
Petitt)
With biomarkers and other study data, researchers can effectively measure
the effectiveness of potential treatments in upcoming clinical trials.
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Patients: study us!
The lead scientist and administrator of the multi-million-dollar PREDICT
study is Jane Paulsen, Ph.D., the co-director of the University of Iowa
Huntington’s Disease Society of America Center of Excellence and
Professor of Psychiatry, Neurology, Psychology, and Neuroscience. From
1991-96, she was a postdoctoral neuropsychology fellow at the University
of California, San Diego (UCSD), where she directed the HD clinical
research program and came into close contact with the local HD
community.
“The desire to move towards earlier detection and identification was really
brought forth at UCSD from the families,” Dr. Paulsen recalled in an
August 6 interview. Such families, she noted, told her: “‘You know, I’ve
been dealing with this for years, and it isn’t validated by the professional
community. I don’t have a diagnosis. A lot of people just think I’m
exaggerating.’
“So just that sense of so many people who are at risk, who might be having
subtle symptoms. When we would see them, we could detect maybe
cognitive or certainly emotional changes that might occur. There’s a lot of
stages that occur before you get the motor signs and diagnosis.
“So the whole PREDICT project was sparked by families in San Diego
saying, ‘I’ve seen this forever, and we need to detect it sooner, before I lose
my job or blow up at my kids or I don’t take care of my home
responsibilities the same or my friends don’t understand me the same or
my family doesn’t understand me the same. If we could move it back and
better understand it, then we could maintain all those additional
components of my life.’ So that was really the motivating factor – trying to
get people to look at it this presymptomatically, before that diagnosis.”
The decision to start PREDICT occurred in 1998 at an executive meeting of
the physician-researcher collective known as the Huntington Study Group,
of which Dr. Paulsen was a founding member. PREDICT formally began in
2001.
With its focus on the asymptomatic, PREDICT could help identify and test
preventative treatments – the “holy grail” of HD research.
“Eventually, when they have a treatment, we want to intervene as soon as
possible, because the sooner we intervene in the brain, the less tissue loss,
the less dysfunction, the less toxicity has occurred,” Dr. Paulsen explained.
“Even if we slow it 15 percent, which is all that they’ve done in other brain
diseases, since HD lasts so many years – we’re thinking 40 years now – 15
percent could be many years where you could maintain a higher level of
functioning.”
You can watch the entire interview with Dr. Paulsen in the video below.
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Fighting Huntington's Disease in the
Heartland: An Interview with Dr. Jane
Paulsen
from Gene Veritas

1:23:41

Maximizing research
PREDICT seeks to “maximize” HD research, Dr. Paulsen said. “We work
with anybody who wants to work on a particular aspect of the disease.”
As the PREDICT flagship, the University of Iowa has collaborated with its
sister PREDICT centers and also partners and subcontractors at other
academic institutions in the U.S. and abroad. The partners focus on
cognitive testing, brain imaging, and motor studies. They include leading
universities such as Johns Hopkins University, Brown University, and the
Massachusetts Institute of Technology. On protein studies, PREDICT
collaborates with Caprion, a private firm.
PREDICT had as many as 33 centers but currently has 27 active sites.
Worldwide some 1,500 individuals, including 1,200 gene-positive, have
participated in PREDICT. The study seeks to follow 1,000 individuals on a
regular basis.
Stimulated largely by PREDICT, Iowa alone has produced a critical mass
of innovative HD research in what Dr. Paulsen described as an “explosion”
in knowledge about the disease over the past decade.
Among the 20-plus projects at Iowa over the past decade, Dr. Paulsen
described research on clinical markers of the disease; biomarkers;
proteomics (the study of HD-associated proteins); bone mass and
metabolism; MRI scans; PET scans; full genome-wide scans (looking at all
the genes in study participants); comparisons of symptoms among people
with the same level of genetic mutation; the impact of discrimination and
stigmatization on gene-positive people; and the possibility that HD might
have vascular, immunological, or inflammatory components.
PREDICT researchers and their collaborators have published numerous
scientific articles on presymptomatic HD and other aspects of the disease.
These include studies seeking to refine cognitive testing; measure the
relationship between estimated disease onset and the likelihood of the use
of antidepressants; detect brain cell loss as an early HD imaging
biomarker; and gauge the loss of perception and processing time in
individuals.
Under Dr. Paulsen’s leadership, Iowa has also taken a key role in the study
of juvenile Huntington’s disease, a form of the condition often given little
attention by researchers because it accounts for just 10 percent of all HD
cases.
Crunching the data
curehd.blogspot.com/2013/08/predicting-huntingtons-disease-in.html
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To help form research questions, search for useful biomarkers among the
large amounts of data collected by PREDICT-HD, and help plan their use
in clinical trials, the project enlists the skills of biostatistician Jeffrey Long,
Ph.D., a professor of psychiatry.
“I mainly focus in tracking progression over time,” said Dr. Long, the
author of a textbook on the open-source computer program known as R,
used widely by statisticians and in the PREDICT research. “We try to make
use of every piece of data because we are appreciative of the time you all
devoted to the study and want to make sure that we maximize the relevant
information for the community.”

Gene Veritas (left) interviewing Dr. Jeffrey Long (photo by Sean
Thompson)
The seven-member bio-statistical team led by Dr. Long analyzes the
different kinds of data collected individually and in combination. The team
also helps draw comparisons between data from gene-positive and genenegative individuals to account for factors such as cognitive loss due to
natural aging.
Additionally, the scientists seek to understand the key relationship
between the level of genetic mutation and the age of onset and severity of
the disease. They have helped identify one key imaging biomarker: the
diminishing size of the brain region known as the putamen before disease
onset. They have also noted an abundance of a particular kind of protein in
the bloodstream of gene-positive individuals.
A special connection
To coordinate visits by PREDICT participants and administer
questionnaires and cognitive testing, the project employs several study
coordinators, including research associate Stephen Cross.
“I’ve fallen in love with the population,” said Cross. “They talk about the
‘HD bug.’ I’ve got the bug. There’s something unique about this
population. I think it’s the family aspect of it. I would feel like I was
abandoning the cause to work with another group.”
With PREDICT since 2008, Cross currently has a caseload of some 80
individuals and their families.
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PREDICT-HD study coordinator Stephen Cross (left) conversing with
Gene Veritas (photo by Sarah Petitt)
“All of them have their lives changed by the genetic testing, regardless of
the results, whether it’s positive or negative,” he observed.
He said that, in the case of gene-positive individuals, especially those from
families who can trace the disease back a number of generations, “I think it
changes their souls, when you know what’s coming in the family, when it’s
in yourself. There’s some kind of interaction in this triad of symptoms –
the movement, the psychiatric and the cognitive. I think you’re special
because of this disease. I feel a spiritual connection with my participants.”
Brain and body scans
“We have many imaging studies,” said Dr. Paulsen. “We’re looking at the
shape changes in the brain.”
Imaging provides a picture of HD without the “need to poke around in the
brain,” Dr. Paulsen noted.
“We already have a very good imaging marker,” she continued. “We can
measure the volume of the part that’s particularly sensitive to
Huntington’s disease, the striata or the basal ganglia. We can see that it
changes a percentage every year of the disease. Even as far back as ten, 15
years prior to diagnosis. But we want to get are even better imaging
markers, maybe ones that are earlier or maybe one that gives us a more
robust signal. So that’s why we have a lot of projects right now that are
really trying to challenge what we can learn from brain imaging.”
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Gene Veritas (above) walks through a metal detector in preparation for a
PREDICT-HD MRI scan performed after MRI radiology technician
Marla Kleingartner (below) secures his head to prevent movement
during the scan (photos by Sarah Petitt).

In addition to markers, imaging has revealed new information about the
extent of the disease, Dr. Paulsen added. Scientists long thought HD
affected only the basal ganglia, the area of the brain responsible for motor
function.
“The imaging data that’s been published over the last decade shows that
it’s much more widespread in the brain,” she said.
With the lack so far of significant HD biomarkers in the blood and urine,
PREDICT is now starting to study CSF collected from a number of its
previous and current participants by way of a spinal tap.
curehd.blogspot.com/2013/08/predicting-huntingtons-disease-in.html
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(I could not donate CSF because a previous lower back injury made the
procedure too risky for me.)
A full-body scan
As a registered nurse, Nancy Downing, Ph.D., takes a holistic approach to
HD-affected individuals, always seeking to improve their quality of life.
Several years ago, an NIH seminar on genetics helped solidify Dr.
Downing’s interest in HD, she said. Today she seeks to integrate genetics
and efforts to improve patients’ quality of life. As a PREDICT researcher,
she has especially focused on the effects of diet and exercise and the way in
which lifestyle affects the expression of genes.
Just two months ago she helped complete a pioneering twelve-month
study in which a group of PREDICT participants underwent dual x-ray
absorptiometry, a scan that reveals the composition of a person’s body
mass (lean, fat, and bone). This same machine is used to detect
osteoporosis.

Nancy Downing, Ph.D., RN, SANE-A (photo courtesy of HDSA Center of
Excellence at the University of Iowa)
Dr. Downing hopes to triangulate the data from this study to help
understand what HD does to areas of the body other than the brain such as
muscle tissue. Evidence already suggests that gene-positive individuals
have a shortage of branched-chain amino acids, necessary for muscle
building and repair, she said.
Dr. Downing’s work supports the growing notion that HD must be seen as
a disease of the body and not just the brain.
Preparing for clinical trials
PREDICT can have an impact on clinical trials and the approach
treatments might take, Dr. Paulsen said.
“It’s kind of a when, where, how question,” she said. “I don’t think any of
those questions is fully answered, so we have more work to do. But we
have answers to those questions that we didn’t have before.
“We didn’t know that there was a when, where, how. We thought that once
they get a diagnosis, we’re going to try to treat them with something that
curehd.blogspot.com/2013/08/predicting-huntingtons-disease-in.html
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we’ve learned from other neurodegenerative diseases. I think in many
ways Huntington’s has opened up that box and made it much larger. It’s a
very exciting time. And I think it will continue. We’re not even close to the
end of the possibilities on where we intervene, (and on) the changes of
Huntington’s disease.”
PREDICT, with its unique database of long-term data on presymptomatic
individuals, could potentially furnish important data for clinical trials, she
added.
“We have this entire cohort,” she explained. “We know exactly how much
change they have over time. If we do an intervention, we will be able to
determine how much change has occurred. No other study can do that,
because if you recruit someone new, you don’t know that individual’s
trajectory. We have each individual’s trajectory. We know what type of
progression they have. If there was a treatment today, this is the group we
should put it in, because we tell exactly what’s going on with that person.”
A potential key treatment
In collaboration with PREDICT and other HD projects at Iowa, the lab of
Beverly Davidson, Ph.D., is engaged in research aiming for a clinical trial
to test a gene-silencing drug that could at least partially halt HD at its root
cause.
This approach would involve the use of RNA interference (RNAi)
molecules permanently introduced into the brain via the injection of a
virus by a neurosurgeon.
Similar to two separate gene-silencing clinical trials planned by Isis
Pharmaceuticals, Inc., and Roche and a team involving Medtronic and the
non-profit CHDI Foundation, Inc., the potential Davidson lab therapy
aims to reduce the production of harmful huntingtin protein by
interrupting the natural translation of the gene into protein.
In HD mouse testing, the lab has demonstrated that RNAi reduces the
toxicity of the bad gene in the brain and alleviates symptoms, Dr. Davidson
said.
She explained that RNAi is currently under study in a clinical trial for
Leber congenital amaurosis, a retinal disorder that leads to blindness in
children.
“They put this into the eyes of these children, and the children are showing
remarkable, remarkable results,” Dr. Davidson said.
Two of the Leber pioneers, Katherine High, M.D., and Jean Bennet,M.D.,
Ph.D., are “collaborating with us to develop the gene therapy vectors for
Huntington’s disease,” Dr. Davidson noted.
Dr. Davidson said her team hopes to start a clinical trial within the next
two years. “That might be aggressive, but we’ve been putting in a lot of
effort in the background in the last year or so,” she said.
To learn more about this project watch my interview with Dr. Davidson in
the video below.
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RNA Interference for Treating
Huntington's Disease: An Interview
with Dr. Beverly Davidson
from Gene Veritas

19:55

PREDICT’s ending, gratitude to funders
Although currently operating at full steam, at least in its current form
PREDICT is scheduled to end on July 1, 2014.
From 2001-2013, PREDICT received a total of $46.8 million in National
Institute of Neurological Disorders and Stroke (NINDS) funding.
Additional support has come from the National Human Genome Research
Institute and the National Institute of Mental Health. The CHDI
Foundation has also infused $15.5 million into the project and is providing
further assistance.
In the last five years of the study, PREDICT received $5.6 million annually
in federal funds from NINDS. The 2013-2014 fiscal year costs are being
covered from funds incurred from previous years.
“I was told that NINDS won’t consider any more budgets over $1 million,”
said Dr. Paulsen, noting the high cost of this kind of research. She said
Iowa would be unable to continue the PREDICT study in its current form
with so little money. Just bringing patients to Iowa is a major expense.
NINDS has experienced cuts in recent years. For fiscal year 2013, the
federal government cut five percent of the NINDS budget as part of the
$85 billion in overall spending cuts determined by Congress, including the
sequestration provisions legislated in 2011.
In addition, CHDI is now shifting its priorities to implementing a new
worldwide HD patient study and database known as Enroll-HD.
Nevertheless, Dr. Paulsen recognized the significance of NINDS funding,
described by one observer as the largest HD project ever funded by the
agency.
“I understand NINDS,” Dr. Paulsen said. “They’ve been cut every year.
We’ve been fortunate to receive funding from them for years, and CHDI
has supplemented us. They had us expand and train some sites to expand.
They have supplemented us when we ran into obstacles. CHDI has been
very forthcoming in assisting. So they’re just always there in the wings
saying, ‘What can we do to make this go better?’ They really want to push
things forward.”
Assessing PREDICT’s impact
Asked to reflect on the ultimate causes of PREDICT’s expected
termination, Dr. Paulsen stated that she’s “not sure I have the right
curehd.blogspot.com/2013/08/predicting-huntingtons-disease-in.html
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answer. I have my opinion. There are centers that have followed research
projects for decades.”
The federal government has supported such ongoing centers for AIDS,
Alzheimer’s, Parkinson’s, and alcoholism, she noted.
However, once again, HD’s status as a rare disease might be leading
officials to treat it as insignificant, Dr. Paulsen indicated. Others might
have misunderstood PREDICT to have failed to innovate.
She rebuts those notions.
“The output of this project has been far greater than many other of the
ongoing centers,” she observed, adding that HD research has contributed
significantly to the study of other conditions. “It’s definitely been a project
that has morphed and kept up and pushed the envelope. It would be nice
to be funded like other centers that just are kind of automatically rolled
over.
“We have to be protective of our resources, but the amount we are learning
has just become exponential. It has grown so much and it isn’t stopping.
Most of the projects I’m talking about are brand new. They’re just starting
to look at CSF, at new imaging markers, at trajectories.”
Despite these setbacks, Dr. Paulsen said that HD research would continue
at Iowa. New grant applications are already in the works, she said.
The Iowa HDSA Center of Excellence will also continue its activities.
My future in PREDICT
In line with PREDICT’s goal of tracking patients over time, the Iowa team
has already notified me that I should return next year for a follow-up
examination, before the July 1, 2014, end date.
Ideally, I should also make a third visit at a later date for the researchers to
have sufficient data points. The uncertain budgetary situation has cast
doubt on that possibility.
Regardless, I feel privileged to have contributed as an HD-positive
individual to the quest for treatments, and I am thankful to the numerous
researchers and support staff of PREDICT-HD and the public and for the
private funding that has made this initiative possible.
(Next time: advocacy meets science and medicine in Iowa and beyond.)
Posted by Gene Veritas at 1:54 PM
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1 comment:
Judy Galasek said...
Hi Gene,
I've been following your blog for a while -- thanks for your
words of wisdom! I just started a blog, too. It's really scary to
come out of the closet. I also go to Iowa for the PREDICTHD
study each year, and really appreciated your article and
pictures!
4:17 PM, September 03, 2013
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